Evofem Biosciences, Inc.

EVFM

US30048L3024

Pharmaceuticals

Delayed OTC Markets Other stock markets 15:38:45 2024-05-15 EDT			5-day change	1st Jan Change
0.0149 ^USD	-1.32%		-2.61%	-76.72%

03-27	Evofem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-27	Evofem Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Evofem Biosciences, Inc. Announces Resignation of Alexander A. Fitzpatrick as the General Counsel and Secretary

October 14, 2022 at 04:14 pm

On October 10, 2022, Alexander A. Fitzpatrick, the General Counsel and Secretary of Evofem Biosciences, Inc. (the “Company”) tendered his resignation to the Company, effective October 14, 2022.

Latest news about Evofem Biosciences, Inc.

Evofem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Evofem Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-27	CI
Transcript : Evofem Biosciences, Inc. - Special Call	03-26
North American Morning Briefing : Dow Set For New -2-	12-14	DJ
Laidlaw Downgrades Evofem Biosciences to Hold From Buy	12-13	MT
Evofem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Transcript : Evofem Biosciences, Inc. Presents at Virtual Investor Ask the CEO Conference, Oct-24-2023 10:00 AM	23-10-24
Evofem Biosciences, Inc. Provides Sales Guidance for the Third Quarter of 2023	23-10-24	CI
Evofem Biosciences, Inc. announced that it has received $3.504807 million in funding	23-09-26	CI
North American Morning Briefing : Treasury Yields Keep Pushing Higher	23-08-17	DJ
Evofem Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Evofem Biosciences, Inc. announced that it has received $0.65 million in funding	23-08-03	CI
Evofem Biosciences, Inc. announced that it has received $1.5 million in funding	23-07-02	CI
North American Morning Briefing : Recession Threat Grows as Further Tightening Likely	23-06-23	DJ
Evofem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-16	CI
North American Morning Briefing : Stock Futures -2-	23-06-16	DJ
MEI Pharma's Finance Chief Brian Drazba to Step Down; Company Names Justin File as Successor	23-06-13	MT
MEI Pharma Names Justin File as Chief Financial Officer	23-06-13	MT
Evofem Biosciences, Inc. Receives Paragraph IV Certification Notice Letter from Padagis Israel Pharmaceuticals Ltd	23-05-05	CI
Evofem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Evofem Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	23-04-26	CI
Evofem Biosciences, Inc. Appoints Ivy Zhang as Secretary	23-04-14	CI
Evofem Biosciences, Inc. Announces CFO Changes	23-04-14	CI
North American Morning Briefing : Further Caution -2-	23-04-06	DJ
Evofem Biosciences, Inc. announced that it has received $0.538461 million in funding	23-04-04	CI

Chart Evofem Biosciences, Inc.

Duration

Period

More charts

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing advanced products to address unmet needs in womenâs sexual and reproductive health. The Companyâs first FDA-approved product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Phexxi is an advanced gel that works to prevent pregnancy without the use of hormones. Phexxi prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Phexxi is designed to address underserved and unmet needs in the birth control market. Additionally, the Company offers women direct access to Phexxi through its telehealth partner. Using this platform, women can have a telehealth visit with a health care provider (HCP) to determine their eligibility for a Phexxi prescription.

Sector

Pharmaceuticals

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.0151

Average target price

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EVOFEM BIOSCIENCES, INC.	-76.72%	937K
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.79%	364B
MERCK & CO., INC.	+20.57%	326B
ABBVIE INC.	+5.59%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+11.04%	167B
PFIZER, INC.	-0.02%	161B

Other Pharmaceuticals